Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 2:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 196,592 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: ALL Clear all
Active, not recruiting Not applicable Interventional

Adapting the HOPE Online Support Intervention to Increase Uptake of Medications for Opioid Use Disorder

NCT04712981
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
HOPE
Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 30, 2026, 2:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Alpha-GPC on Muscle Power, GH Levels, and Cognitive Function

NCT06690619
View directory record Official record
Conditions
Cognition - Other, Strength Outcomes
Interventions
Placebo, 315 mg Alpha-GPC, 630 mg Alpha-GPC
Dietary Supplement
Lead sponsor
Lindenwood University
Other
Eligibility
25 Years to 55 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Canfield, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 30, 2026, 2:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study to Evaluate the Safety and Immunogenicity of Heterologous Boost Immunizations With MVA-CMDR

NCT01889719
View directory record Official record
Conditions
HIV
Interventions
MVA-CMDR
Biological
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 62 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 30, 2026, 2:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Treatment of Androgenic Alopecia in Males

NCT00947219
View directory record Official record
Conditions
Androgenetic Alopecia, Hair Loss, Male Pattern Baldness
Interventions
HairMax LaserComb, Control device
Device
Lead sponsor
Lexington International, LLC
Industry
Eligibility
25 Years to 60 Years · Male only
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
3
States / cities
West Palm Beach, Florida • Hackensack, New Jersey • High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 30, 2026, 2:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults

NCT05397119
View directory record Official record
Conditions
Influenza, Pandemic
Interventions
BW-1014: 25 µg rH5 in 20% NE - pipette - IN, BW-1014: 50 µg rH5 in 20% NE - pipette - IN, BW-1014: 100 µg rH5 in 20% NE - pipette - IN, rH5 (100 µg) control - pipette - IN, Saline (Placebo) - pipette - IN, H5N1 IIV - IM
Biological
Lead sponsor
BlueWillow Biologics
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 30, 2026, 2:21 AM EDT
Completed No phase listed Observational Results available

Observational, Real World Study Of Inflectra In Patients With Inflammatory Bowel Disease

NCT03801928
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), Crohn's Disease (CD), Ulcerative Colitis (UC)
Interventions
Inflectra
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
San Diego, California • Hamden, Connecticut • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Oct 30, 2026, 2:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Family Nurture Intervention, A Group Model in Connecticut

NCT02970565
View directory record Official record
Conditions
Behavior Problem, Development Delay, Emotional Disturbance, Family Conflict
Interventions
Family Nurture Intervention, Nutrition and Play Intervention
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
24 Months to 54 Months
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Cos Cob, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 30, 2026, 2:21 AM EDT
Recruiting Phase 2 Interventional

A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC

NCT06597565
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Gemcitabine, ACR-368
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 30, 2026, 2:21 AM EDT
Completed Phase 2 Interventional Results available

Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

NCT03213665
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Low Grade Glioma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Hodgkin Lymphoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Hodgkin Lymphoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Soft Tissue Sarcoma, Rhabdoid Tumor, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Wilms Tumor
Interventions
Tazemetostat
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
115
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 30, 2026, 2:21 AM EDT
Terminated Phase 3 Interventional Results available

Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML

NCT05020665
View directory record Official record
Conditions
Nucleophosmin 1-mutated Acute Myeloid Leukemia
Interventions
Entospletinib, Placebo, Cytarabine, Anthracycline
Drug
Lead sponsor
Kronos Bio
Industry
Eligibility
18 Years to 74 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
10
States / cities
Duarte, California • Los Angeles, California • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Oct 30, 2026, 2:21 AM EDT
Completed Not applicable Interventional Results available

Primary Care-based Study of an Online Workshop for Family Caregivers of PLWD

NCT06928467
View directory record Official record
Conditions
Family Caregivers, Dementia, Self-management, Depression, Internet-based Intervention
Interventions
Building Better Caregivers workshop
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
San Francisco, California • Cooperstown, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 30, 2026, 2:21 AM EDT
Completed No phase listed Observational

Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia

NCT01158807
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia
Interventions
Not listed
Lead sponsor
Unity Health Toronto
Other
Eligibility
Not listed
Enrollment
2,272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
14
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 30, 2026, 2:21 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder

NCT00798707
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Desvenlafaxine Succinate Sustained-Release (DVS SR), placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
709 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
19
States / cities
Arcadia, California • Beverly Hills, California • Cerritos, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2011 · Synced Oct 30, 2026, 2:21 AM EDT
Not yet recruiting Not applicable Interventional

Youth Suicide Prevention: CAMS-BI vs. Safety Planning in a Randomized Trial

NCT07628192
View directory record Official record
Conditions
Suicidal Ideation, Suicide Attempt, Safety Plan, Depression / Major Depressive Disorder, Hopelessness
Interventions
CAMS Brief Intervention, Stanley-Brown Safety Planning Intervention
Behavioral
Lead sponsor
The Cleveland Clinic
Other
Eligibility
12 Years to 17 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 30, 2026, 2:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

TYRO Champion Dads Project Study

NCT05256992
View directory record Official record
Conditions
Fathers
Interventions
Standard Servies + Ray of Hope Curriculum, Standard Services
Other
Lead sponsor
Midwest Evaluation & Research
Other
Eligibility
18 Years and older · Male only
Enrollment
748 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 30, 2026, 2:21 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Subject Satisfaction With AbobutulinumtoxinA Treatment

NCT03687736
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
AbobotulinumtoxinA
Biological
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Oct 30, 2026, 2:21 AM EDT
Completed Not applicable Interventional

Evaluation of the Effect of Spry Belt Treatment on Bone Turnover Marker Profile

NCT05457036
View directory record Official record
Conditions
Osteopenia, Low Bone Density
Interventions
Spry Belt, Sham Spry Belt
Device
Lead sponsor
Bone Health Technologies, Inc.
Industry
Eligibility
50 Years and older · Female only
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
San Francisco, California • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Oct 30, 2026, 2:21 AM EDT
Terminated Not applicable Interventional Results available

Treatment of Partial-Thickness Rotator Cuff Tears

NCT03734536
View directory record Official record
Conditions
Arthroscopic Surgical Treatment of High-grade (>50%) Partialthickness
Interventions
REGENETEN™ Bioinductive Implant, Arthroscopic repair of the high-grade (>50%) partial-thickness
Device
Lead sponsor
Smith & Nephew, Inc.
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
10
States / cities
Gainesville, Florida • Jacksonville Beach, Florida • Rome, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 30, 2026, 2:21 AM EDT
Terminated Phase 2 Interventional Results available

HEROIC (Heparin Requirement in Counterpulsation)

NCT00445211
View directory record Official record
Conditions
Cardiogenic Shock
Interventions
Heparin, Without Heparin
Drug · Other
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated May 19, 2017 · Synced Oct 30, 2026, 2:21 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

NCT06191744
View directory record Official record
Conditions
Follicular Lymphoma (FL)
Interventions
Epcoritamab, Prednisone, Rituximab, Lenalidomide, Doxorubicin, Vincristine, Cyclophosphamide, Obinutuzumab, Bendamustine
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
1,095 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2037
U.S. locations
58
States / cities
Fresno, California • San Diego, California • Santa Barbara, California + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 30, 2026, 2:21 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Light at Night Study

NCT04251234
View directory record Official record
Conditions
Bipolar Disorder, Light Sensitivity
Interventions
Light intensity, ~30 lux, Baseline light intensity, <1 lux
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 45 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Oct 30, 2026, 2:21 AM EDT
Completed Not applicable Interventional Results available

Testing the Impact of Smartphone-based Messaging to Support Young Adult Smoking Cessation - Pilot

NCT05991934
View directory record Official record
Conditions
Tobacco Cigarette Smoking
Interventions
Smartphone-based intervention messages
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 30 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Oct 30, 2026, 2:21 AM EDT
Completed Not applicable Interventional Results available

Convection Enhanced Delivery of CSF in DBS for Parkinson's

NCT03540134
View directory record Official record
Conditions
Parkinson Disease
Interventions
Intracerebral Infusion of Autologous Cerebral Spinal Fluid
Device
Lead sponsor
Jeff Elias, MD
Other
Eligibility
30 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 30, 2026, 2:21 AM EDT
Completed Phase 2 Interventional

Comparative Effectiveness of a Breath-operated Albuterol Inhaler in Asthma Patients With Poor Inhaler Technique

NCT00054964
View directory record Official record
Conditions
Asthma
Interventions
Albuterol HFA-BOI, Albuterol HFA-MDI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Oct 30, 2026, 2:21 AM EDT